These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6231187)

  • 1. Control of the immune complex-complement interaction by protein H of the alternative complement pathway and the natural inhibitor heparin.
    Spycher MO; Nydegger UE
    Eur J Immunol; 1984 Mar; 14(3):276-9. PubMed ID: 6231187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin-mediated shifting of immune complexes to increased complement-dependent solubility and immunoadherence.
    Spycher MO; Späth PJ; Häsig A; Nydegger UE
    Mol Immunol; 1984 Jun; 21(6):497-505. PubMed ID: 6431266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of immune complex and zymosan-mediated anaphylatoxin generation by proteins B and H of the alternative complement pathway.
    Kings M; Nydegger UE; de Weck AL
    Immunology; 1984 Jan; 51(1):123-31. PubMed ID: 6197357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
    Gadd KJ; Reid KB
    Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
    Waldo FB; Forristal J; Beischel L; West CD
    J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The attachment of serum- and plasma-derived C3 to solid-phase immune aggregates and its relation to complement-mediated solubilization of immune complexes.
    Baatrup G; Svehag SE; Jensenius JC
    Scand J Immunol; 1986 Apr; 23(4):397-406. PubMed ID: 3486458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solubilization of immune precipitates by six isolated alternative pathway proteins.
    Fujita T; Takata Y; Tamura N
    J Exp Med; 1981 Dec; 154(6):1743-51. PubMed ID: 6459396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).
    Schifferli JA; Steiger G; Paccaud JP
    Clin Exp Immunol; 1986 May; 64(2):407-14. PubMed ID: 3488858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
    Kazatchkine MD; Fearon DT; Silbert JE; Austen KF
    J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c.
    Medof ME; Prince GM; Mold C
    Proc Natl Acad Sci U S A; 1982 Aug; 79(16):5047-51. PubMed ID: 6214790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
    Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
    Takata Y; Tamura N; Fujita T
    J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
    Nilsson-Ekdahl K; Nilsson B
    Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solubilization of immune precipitates by complement in the absence of properdin or factor D.
    Späth PJ; Pascual M; Meyer-Hänni L; Schaad UB; Schifferli JA
    FEBS Lett; 1988 Jul; 234(1):131-4. PubMed ID: 2968916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement for human red blood cells in inactivation of C3b in immune complexes and enhancement of binding to spleen cells.
    Medof ME; Lam T; Prince GM; Mold C
    J Immunol; 1983 Mar; 130(3):1336-40. PubMed ID: 6218206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes.
    Pfaffenbach G; Lamm ME; Gigli I
    J Exp Med; 1982 Jan; 155(1):231-47. PubMed ID: 7054357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-surface regulation of the human alternative pathway of complement. Sheep but not rabbit erythrocytes express factor I-dependent cofactor activity.
    Ezzell JL; Parker CJ
    Scand J Immunol; 1992 Jul; 36(1):79-87. PubMed ID: 1535452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    J Immunol; 1983 Oct; 131(4):1930-5. PubMed ID: 6225800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of factors H and I for the adherence of C3b-coated erythrocytes to cells.
    Scheiner O; Schulz TF; Schmid HU; Lambris JD; Alsenz J; Dierich MP
    Immunobiology; 1983 Aug; 165(2):211-24. PubMed ID: 6226591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.